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Studies of oncogenic viruses have made seminal contributions to the molecular biology of cancer. 
Key discoveries include the identification of viral oncogenes and cellular proto-oncogenes, elucidation 
of signal transduction pathways, and identification of tumor suppressor genes. The origins of cancer 
virology began almost exactly one hundred years ago with the discovery of avian sarcoma and acute 
leukemia  viruses—RNA-containing  viruses  of  the  retrovirus  family.  The  study  of  animal  cancer 
viruses accelerated beginning in the late 1960s and early 1970s, with the discovery of DNA viruses 
that could transform cells in culture, and the development of quantitative assays for transformation by 
DNA and RNA-containing tumor viruses. The discovery of reverse transcriptase in retroviruses in 
1970 also greatly accelerated research on these viruses. Indeed RNA and DNA tumor viruses led the 
way in cancer molecular biology during this era before molecular cloning. It was possible to physically 
purify virus particles and generate specific hybridization probes for viral DNA and RNA at a time 
when it was not possible to analyze cellular genes in the same manner. 
Laboratory studies on RNA and DNA tumor viruses (many of them animal viruses) are highly 
relevant to human cancer. First, many of the principles of viral oncogenesis elucidated by these studies 
are directly applicable to human cancers, including those that are not caused by viruses. In addition, a 
significant percentage of human cancers worldwide (~15%) have a viral involvement. Human DNA 
tumor  viruses  include  human  papillomavirus  (HPV,  high  risk  strains),  Merkel  cell  polyomavirus 
(MPV),  the  gammaherpesviruses  Epstein-Barr  virus  (EBV)  and  Kaposi’s  sarcoma  herpesvirus 
(KSHV), and hepatitis B virus (HBV). Human RNA viruses that cause cancer include the retrovirus 
Human T-cell Leukemia virus type I (HTLV-I) and the flavivirus hepatitis C virus (HCV). In addition, 
AIDS  is  caused  by  a  retrovirus  (HIV-1  and  -2);  a  major  complication  of  the  immunodeficiency 
characteristic of AIDS is the development of cancers. Most of these cancers have an underlying viral 
involvement (e.g. KSHV and Kaposi’s sarcoma, which was first discovered in AIDS patients).  
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The articles in this issue are part of a planned larger collection that will also include chapters on 
DNA tumor viruses, to be published at a later date. The bulk of the contributions focus on retroviruses, 
since they have been actively studied for more than fifty years. Oncogenic retroviruses can be divided 
into acute transforming viruses that carry viral oncogenes and induce tumors rapidly, vs. non-acute 
retroviruses that do not carry oncogenes and which induce tumors more slowly. The prototypic acute 
transforming retrovirus is Rous sarcoma virus (RSV) which carries the v-src oncogene. V-src was 
derived from the cellular proto-oncogene c-src. The other acute transforming retroviruses also carry 
captured versions of cellular proto-oncogenes. As a class the cellular proto-oncogenes stimulate cell 
growth or division, and the viral oncogenes derived from them constitutively stimulate cell growth or 
division by employing the same pathways. Acute transforming retroviruses and their oncogenes were 
intensively studied in the past, after which attention shifted to the normal functions and regulation of 
the cellular proto-oncogenes. Since they have been extensively reviewed in the past [1], they were not 
included in this issue. 
Non-acute  retroviruses  typically  induce  tumors  by  transcriptionally  activating  cellular  proto-
oncogenes; this generally results from influence of the viral long terminal repeats (LTRs) on the proto-
oncogenes—LTR  activation  of  proto-oncogenes.  These  mechanisms,  and  other  mechanisms  of 
oncogenesis  by  non-acute  retroviruses  are  reviewed  in  the  chapter  by  Fan  and  Johnson  [2]. 
Implications of non-acute retroviral oncogenesis to safety in gene therapy trials are also discussed. 
The other chapters on retroviruses summarize work on some of the oncogenic retroviruses that are 
under  current  investigation.  Cmarik  and  Ruscetti  [3]  review  leukemogensis  by  the  Friend  MuLV 
complex, which consists of an acute transforming virus SFFV as well as a helper virus (F-MuLV). 
Friend SFFV is interesting because its oncogene is a deleted version of a retroviral envelope protein 
that is a recombinant between F-MuLV and an endogenous MuLV-related provirus. The mechanisms 
by which the SFFV env protein activates signal transduction pathways have been well-studied and are 
reviewed. The Friend virus complex has also provided substantial insights on insertional oncogenesis, 
including inactivation of the p53 tumor suppressor gene. Ross [4] reviews replication and oncogenesis 
by  murine  mammary  tumor  virus  (MMTV).  MMTV  initially  infects  cells  of  the  immune  system 
(dendritic cells, T and B lymphocytes) before trafficking to the mammary gland where insertional 
activation of proto-oncogenes and mammary carcinogenesis occurs. MMTV is also interesting because 
it encodes additional proteins (besides the standard retroviral Gag, Pol and Env proteins), including a 
viral superantigen (Sag) and a small regulatory protein Rem that are both important for replication in 
vivo. Studies of MMTV have also provided insight into a host restriction factor APOBEC3. Jaagsiekte 
sheep retrovirus replication and oncogenesis is reviewed by Hofacre and Fan [5]. JSRV (like MMTV) 
is a betaretrovirus, and it induces a transmissible lung cancer in sheep. While JSRV has not captured a 
cellular  proto-oncogene,  the  envelope  protein  of  this  virus  also  functions  as  an  oncogene.  The 
mechanisms  by  which  JSRV  Env  induces  oncogenic  transformation  are  discussed.  Like  MMTV,  
JSRV  also  encodes  a  small  regulatory  protein  Rej  that  is  necessary  for  efficient  translation  of  
unspliced viral RNA. 
Rovnak  and  Quackenbush  [6]  review  oncogenesis  by  epsilonretroviruses,  in  particular  walleye 
dermal sarcoma virus (WDSV). WDSV causes dermal sarcomas in walleye pike; there is striking 
seasonal  variation  in  that  the  tumors  occur  during  the  winter,  and  they  slough  off  during  the 
springtime. The tumors express very little infectious virus, but virus production occurs during the Viruses 2011, 3                                       
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spring as tumors are being sloughed.  WDSV encodes additional proteins, one of which is a viral 
cyclin. This cyclin appears to function as both a repressor of viral transcription and an oncogene.  
Kannian  and  Green  [7]  review  replication  and  oncogenesis  by  HTLV-I.  HTLV-I  and  other 
deltaretroviruses encode a series of additional proteins derived by alternate splicing into the X region 
of the genome. The mechanisms of function of these proteins and their potential roles in oncogenesis 
are  described.  It  is  noteworthy  that  leukemogenesis  by  HTLV-I  is  quite  inefficient,  with  a  low 
percentage of infected people ultimately developing disease, after decades. The roles of the viral Tax 
and HBZ proteins in oncogenesis are summarized. 
The  other  RNA  virus  associated  with  cancer  is  hepatitis  C  virus  (HCV),  reviewed  by  
Banerjee et al. [8]. A noteworthy feature of HCV infection in vivo is that a significant fraction of 
individuals infected by HCV are unable to clear the infection. The persistent infection can lead to 
chronic liver damage and ultimately development of hepatocellular carcinoma. It is interesting that the 
unrelated  HBV  can  also  establish  persistent  infection  and  those  individuals  are  also  at  risk  for 
developing liver cancer. In this article the potential roles of several viral proteins in causing cellular 
damage that could lead to tumorigenesis in persistently infected individuals are described. 
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